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Abstract
Background Hepatocyte nuclear factor 4a (HNF4A) is a member of the nuclear receptor family of ligand-activated
transcription factors. HNF4A mutations cause hyperinsulinaemic hypoglycaemia in early life and maturity-onset
diabetes of the young. Regular screening of HNF4A mutation carriers using the oral glucose tolerance test has been
recommended to diagnose diabetes mellitus at an early stage. Glucagon-like peptide-1 and glucose-dependent
insulinotropic polypeptide are incretin hormones, responsible for up to 70% of the secreted insulin after a meal in
healthy individuals. We describe, for the first time, gradual alteration of glucose homeostasis in a patient with HNF4A
mutation after resolution of hyperinsulinaemic hypoglycaemia, on serial oral glucose tolerance testing. We also
measured the incretin response to a mixed meal in our patient.
Case report Our patient was born with macrosomia and developed hyperinsulinaemic hypoglycaemia in the neonatal
period. Molecular genetic analysis confirmed HNF4A mutation (p.M116I, c.317G>A) as an underlying cause of
hyperinsulinaemic hypoglycaemia. Serial oral glucose tolerance testing, after the resolution of hyperinsulinaemic
hypoglycaemia, confirmed the diagnosis of maturity-onset diabetes of the young at the age of 10 years. Interestingly, the
intravenous glucose tolerance test revealed normal glucose disappearance rate and first-phase insulin secretion. Incretin
hormones showed a suboptimal rise in response to the mixed meal, potentially explaining the discrepancy between the
oral glucose tolerance test and the intravenous glucose tolerance test.
Conclusions Maturity-onset diabetes of the young can develop as early as the first decade of life in persons with an
HNF4A mutation. Impaired incretin response might be contributory in the early stages of HNF4A maturity-onset
diabetes of the young.
Diabet. Med. 31, e11–e15 (2014)
Introduction
Hepatocyte nuclear factor 4a (HNF4A) is a member of the
steroid/thyroid hormone receptor superfamily and is most
highly expressed in the liver, kidney, pancreatic islets and
intestine [1,2]. HNF4A is a major activator of hepatocyte
nuclear factor 1a (HNF1A), which in turn activates the
expression of a large number of liver-specific genes, including
those involved in glucose, cholesterol and fatty acid metab-
olism [3]. Specifically in the pancreatic islets, HNF4A has
been shown to control the expression of genes involved in
glucose-stimulated insulin secretion [4,5]. HNF4A mutations
cause hyperinsulinaemic hypoglycaemia and maturity-onset
diabetes of the young (MODY) [6–8]. Annual screening of
HNF4A-mutation carriers with oral glucose tolerance testing
was recommended to diagnose diabetes mellitus at an early
stage [7].
Glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide are incretin hormones, which
augment the magnitude of meal-stimulated insulin secretion
from islet b-cells in a glucose-dependent manner [9].
We describe, for the first time, the gradual alteration in
glucose homeostasis and development of MODY in the
HNF4A-mutation carrier after resolution of hyperinsulinae-
mic hypoglycaemia, on prospective follow-up with an
annual oral glucose tolerance test. We also report the
GLP-1 and glucose-dependent insulinotropic polypeptide
response to the mixed-meal test at the onset of diabetes
mellitus.
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Research design and methods
KCNJ11, ABCC8 and HNF4A sequencing
Genomic DNA was extracted from peripheral leukocytes
using standard procedures, and the coding exons and
intron/exon boundaries of the ABCC8, KCNJ11 and
HNF4A genes were amplified by polymerase chain reaction
(PCR). HNF4A analysis included the coding exons 1d–10
and the P2 pancreatic promoter. PCR products were
sequenced using standard methods on an ABI 3730
sequencer (Applied Biosystems, Warrington, UK) and were
compared with the published sequence NM_000457.3
(exons 2–10) and AY680697 (exon 1d only) using Muta-
tion Surveyor v3.2 (SoftGenetics, State College, PA, USA)
[10].
Oral glucose tolerance test
An oral glucose tolerance test (glucose load 1.75 g/kg) was
performed in accordancewith standard recommendations and
the results were interpreted according to published World
Health Organization (WHO) diagnostic criteria [11,12].
Intravenous glucose tolerance test
After an overnight fast of 12 h, 0.5 g/kg of glucose as a 20%
solution was infused within 2 min through an intravenous
catheter in the antecubital region. Blood samples were
obtained at –10, –5, 0, 1, 3, 5, 10, 15, 20, 30, 45 and 60 min
through a second intravenous catheter for estimation of blood
glucose and serum insulin. The glucose disappearance rate K
(%/min) was calculated according to 0.693 9 100/t1/2 (in min),
where t1/2 was the time span (min) required for glucose to fall
by 50% from its level at 10 min [12]. The first-phase insulin
releasewas calculated by the area under the insulin stimulation
curve between 0 and 10 min [12].
Mixed-meal tolerance test
The mixed-meal tolerance test was performed after an
overnight fast of 12 h. A standardized breakfast was ingested
over 10 min, calculated by a dietician based on the total
caloric needs of the patient (25–30% of their daily caloric
intake; 50% of the calories as carbohydrates, 33% lipids and
17% proteins). Blood samples were collected at 0, 15, 30, 45
and 60 min for estimation of blood glucose, serum insulin,
total glucose-dependent insulinotropic polypeptide and
active GLP-1. The area under curve was estimated by the
linear trapezoidal method from the concentration time curve.
Measurement of GLP1 and glucose-dependent insulinotropic
polypeptide
Blood was collected in chilled EDTA-treated tubes containing
DPP-4 inhibitor (10 ll/ml blood:Millipore,Watford, UK) and
aprotonin (trasylol 5000 KIU/ml blood: Bayer, Newbury,
UK). Blood was processed according to the manufacturers’
instructions for the measurement of hormones using commer-
cially available assays. Total glucose-dependent insulinotropic
polypeptide and active GLP-1 were determined using
commercially available human ELISA kits according to the
manufacturer’s guidelines (Millipore). All samples were
performed in duplicate.
Case report
We describe a male Caucasian patient, who was born with
macrosomia [birthweight 4060 g at 39 weeks of gestation;
+1.44 standard deviation score (SDS)] and who developed
neonatal hypoglycaemia requiring a high glucose infusion
rate (18.5 mg kg–1 min–1) to maintain normoglycaemia.
There was no family history of diabetes mellitus. Investiga-
tions revealed inappropriately elevated serum insulin and
inappropriately low b-hydroxybutyrate and non-esterified
fatty acids during an episode of hypoglycaemia on three
occasions, confirming hyperinsulinaemic hypoglycaemia.
Serum cortisol, lactate, ammonia, plasma aminoacids,
carnitine profile and urine organic acids were normal.
Molecular genetic testing for mutation in ABCC8/KCNJ11
was negative. Hyperinsulinaemic hypoglycaemia was suc-
cessfully managed with diazoxide. A 24-h blood glucose
profile and controlled fasting studies were carried out at
regular intervals until the age of 18 months, at which age his
hyperinsulinaemic hypoglycaemia resolved.
At the age of 5 years, after HNF4A mutations were first
reported as a cause of macrosomia and neonatal hyperins-
ulinaemic hypoglycaemia, he underwent molecular genetic
testing and was identified to have a de novo heterozygous
HNF4A mutation (p.M116I, c.317G>A) [13].
Oral glucose tolerance test
Annual monitoring with an oral glucose tolerance test
revealed impaired glucose tolerance and development of
diabetes mellitus according to WHO diagnostic criteria
(Table 1) [11]. At the diagnosis of diabetes mellitus, he
was prepubertal with a bilateral testicular volume of 2 ml.
What’s new?
• This study reports the first patient with an HNF4A
mutation to have been serially monitored from the
diagnosis of hyperinsulinaemic hypoglycaemia to matu-
rity-onset diabetes of the young.
• We describe, for the first time, incretin response in a
patient with HNF4A maturity-onset diabetes of the
young, which has the potential to influence the man-
agement of these patients.
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His HbA1c was 40 mmol/mmol (5.8%) and autoantibodies
(GAD 65 and islet-cell) were negative. His serial BMI and
BMI SDS were normal (Table 1).
Intravenous glucose tolerance test
An intravenous glucose tolerance test (Fig. 1) revealed
normal glucose disappearance rate (1.38% per min; normal
response > 1.2% per min) and first-phase insulin secretion
(2.7 nmol l1 min1 normal 1.4–5.3 nmol l–1 min–1), which
were not indicative of insulin secretion defect [12].
Mixed-meal tolerance test
To understand the reasons for the discrepancy between
diabetic oral glucose tolerance test response and normal
intravenous glucose tolerance test response, we measured the
incretin hormones in response to the mixed-meal tolerance
test (Fig. 2). The 30-min areas under the curve for active
GLP-1 and total glucose-dependent insulinotropic polypep-
tide were 350.9 and 740.2 pmol/l, respectively, which are
lower than the sparse data on these hormones in the
literature in this age group.
Discussion
MODY is a genetically heterogeneous monogenic form of
diabetes mellitus, characterized by early onset, usually before
25 years of age and often in adolescence or childhood, and
by autosomal dominant inheritance [14]. Heterozygous
mutations in the genes encoding the glycolytic enzyme
glucokinase and the transcription factors, HNF-1a, HNF-4a
and HNF1b have been shown to cause MODY. Clinical
studies have shown normal insulin sensitivity, but reduced
glucose-stimulated insulin secretion in subjects with pre-
diabetes with HNF-4A MODY, suggesting that pancreatic
b-cell dysfunction rather than insulin resistance is the
primary defect in this disorder [15].
Recently, HNF4A mutations have been shown to cause
macrosomia and hyperinsulinaemic hypoglycaemia (tran-
sient and persistent) in early life [7,8]. Hence, in HNF4A
mutation carriers, there would need to be a switch from
increased insulin secretion in utero and neonatal life to
decreased glucose-stimulated insulin secretion in later
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active glucagon-like peptide 1 (GLP-1) response to the mixed-meal
tolerance test.
Table 1 Oral glucose tolerance test
Age 7 years 8 years 9 years 10 years
BMI,
kg/m2
(SDS)
15.25
(–0.22)
15.8
(+0.05)
17.6
(+0.75)
19.9
(+1.17)
Time
Blood glucose
(mmol/l)
Serum
insulin
(mU/l)
Blood
glucose
(mmol/l)
Serum
insulin
(mU/l)
Blood
glucose
(mmol/l)
Serum insulin
(mU/l) Blood glucose (mmol/l)
Serum
insulin (mU/l)
C-peptide
(pmol/l)
–30 min 4.0 < 2.0 4.0 < 2.0 4.3 < 2.0
0 min 3.6 < 2.0 3.9 < 2.0 4.2 < 2.0 4.8 5.6 440
30 min 8.8 39.8 8.6 39.6 6.9 23 9.2 47.1 1903
60 min 7.7 39.1 8.5 26.4 9.5 30 11.7 66.7 2522
90 min 6.7 22.5 6.8 17.0 8.5 21 11.5 44.1 2214
120 min 6.8 23.6 8.3 28.9 9.3 26 12.3 35.9 1956
150 min 3.4 6.6 6.2 13.8 13.3 36.3 1926
180 min 3.1 < 2.0 3.2 < 2.0 8.4 17.0 1202
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life. The molecular basis for the differential aspects of
HNF-4a deficiency on b-cell function and insulin secretion
in neonates and later in life and the exact timing of the
switch from hyperinsulinaemia to hypoinsulinaemia are
unknown.
We describe the first patient with an HNF4A mutation to
have been serially monitored with oral glucose tolerance
testing through to MODY from hyperinsulinaemic hypo-
glycaemia. The patient was macrosomic at birth and exhib-
ited hyperinsulinaemic hypoglycaemia in the neonatal period
and infancy. Annual oral glucose tolerance test monitoring
highlighted gradually worsening glucose tolerance (impaired
oral glucose tolerance test). At age 10 years, he fulfilled the
WHO oral glucose tolerance test criteria for diabetes mellitus
[11].
Surprisingly, intravenous glucose tolerance testing demon-
strated a normal glucose disappearance rate (K) and first-
phase insulin secretion, contradictory to what one would
expect in MODY (K 1.38% per min; normal response
> 1.2%, first-phase insulin secretion 2.7 nmol l–1 min–1;
normal 1.4–5.3 nmol l–1 min–1). Similar to our results, when
assessed by intravenous glucose tolerance test, Herman et al.
[15] did not find any significant difference in insulin secretion
in HNF4A mutation carriers without diabetes as compared
with control subjects either. As our patient has been
diagnosed at a very early stage of MODY, it is possible that
his insulin secretion as assessed by intravenous glucose
tolerance test is still preserved.
As our patient had a diabetic response to the oral glucose
tolerance test and a relatively normal response to the
intravenous glucose tolerance test, we hypothesized a
suboptimal glucose-dependent insulinotropic polypeptide
and GLP-1 rise in response to oral glucose/meal in HNF4A
mutation carriers. Glucose-dependent insulinotropic poly-
peptide and GLP-1 are peptide hormones, responsible for up
to 70% of the secreted insulin after a meal in healthy
individuals [16].
In response to a mixed-meal tolerance test, the 30-min
areas under the curve for GLP-1 and glucose-dependent
insulinotropic polypeptide were 350.9 and 740.2 pmol/l,
respectively. Rask et al. reported a 30-min area under
the curve for GLP-1 and glucose-dependent insulino-
tropic polypeptide after oral glucose as 460  60 and
1491  136 pmol/l, respectively, in subjects with impaired
glucose tolerance [17]. Huml et al. measured GLP-1 and
glucose-dependent insulinotropic polypeptide in healthy
children, but at a single time point of 90 min after the
standardized breakfast [18]. Unfortunately, there are no
normative data on GLP-1 and glucose-dependent insulino-
tropic polypeptide in healthy control children. Comparing
the results, it does seem that our patient mounted a lower
GLP-1 and glucose-dependent insulinotropic polypeptide
response to the mixed-meal tolerance test, potentially
explaining the discrepancy for responses to the oral glucose
tolerance test and intravenous glucose tolerance test.
However, there are limitations to comparing our results
with adult subjects with impaired glucose tolerance from
another cause.
From our data, it is plausible that incretin response might
be impaired and contributory to glucose intolerance in the
preclinical stages in some patients with HNF4A MODY.
Once glucose intolerance sets in, chronic exposure to
supraphysiologic concentrations of glucose over several
months can lead to gradual loss of insulin gene expression
[19,20].
In conclusion, we report the first patient with HNF4A
hyperinsulinaemic hypoglycaemia to have switched to
maturity-onset diabetes of the young on serial oral glucose
tolerance testing. Impaired glucose tolerance can develop
within the first decade of life in these patients. Our findings
suggest a possibility of impaired incretin response and this
is an exciting area to be explored in HNF4A maturity-onset
diabetes of the young. More HNF4A-positive subjects with
pre-diabetes and diabetes need to be studied to understand
the impact of the HNF4A mutation on incretin effect.
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